Calamos Advisors LLC Makes New $3.12 Million Investment in MiMedx Group, Inc. (NASDAQ:MDXG)

Calamos Advisors LLC bought a new stake in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 355,534 shares of the company's stock, valued at approximately $3,118,000. Calamos Advisors LLC owned approximately 0.31% of MiMedx Group as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in MDXG. Custom Index Systems LLC acquired a new stake in shares of MiMedx Group during the 4th quarter valued at approximately $121,000. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of MiMedx Group during the 4th quarter valued at approximately $1,594,000. Allspring Global Investments Holdings LLC raised its position in shares of MiMedx Group by 6.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 211,571 shares of the company's stock valued at $1,855,000 after acquiring an additional 13,628 shares in the last quarter. Raymond James & Associates acquired a new stake in shares of MiMedx Group during the 4th quarter valued at approximately $114,000. Finally, SG Americas Securities LLC raised its position in shares of MiMedx Group by 105.8% during the 4th quarter. SG Americas Securities LLC now owns 81,640 shares of the company's stock valued at $716,000 after acquiring an additional 41,970 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 20,381 shares of the stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $7.95, for a total value of $162,028.95. Following the completion of the transaction, the chief accounting officer now owns 479,959 shares of the company's stock, valued at $3,815,674.05. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, COO Ricci S. Whitlow sold 15,271 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $8.01, for a total value of $122,320.71. Following the completion of the transaction, the chief operating officer now owns 401,050 shares of the company's stock, valued at $3,212,410.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO William Frank Iv Hulse sold 20,381 shares of the firm's stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total value of $162,028.95. Following the transaction, the chief accounting officer now directly owns 479,959 shares of the company's stock, valued at approximately $3,815,674.05. The disclosure for this sale can be found here. Over the last quarter, insiders sold 51,145 shares of company stock valued at $409,378. 19.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on MDXG. Lake Street Capital began coverage on MiMedx Group in a research report on Thursday, March 7th. They set a "buy" rating and a $12.00 price target on the stock. Mizuho upped their price objective on MiMedx Group from $13.00 to $14.00 and gave the stock a "buy" rating in a research note on Friday, March 1st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $12.25.

MiMedx Group Stock Performance

MDXG traded up $0.13 during trading on Friday, reaching $6.29. 691,192 shares of the company were exchanged, compared to its average volume of 778,720. The stock has a market cap of $924.38 million, a P/E ratio of 19.66 and a beta of 1.32. The firm has a 50 day moving average of $7.64 and a 200 day moving average of $7.60. The company has a current ratio of 3.57, a quick ratio of 3.11 and a debt-to-equity ratio of 0.34. MiMedx Group, Inc. has a 52 week low of $3.37 and a 52 week high of $9.27.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). MiMedx Group had a return on equity of 41.12% and a net margin of 14.49%. The business had revenue of $86.83 million during the quarter, compared to the consensus estimate of $85.58 million. On average, sell-side analysts forecast that MiMedx Group, Inc. will post 0.33 EPS for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.